Global Ocular Drug Delivery Market Research Report 2025

Publication ID:

PB501251078

Publication Date:

January 3, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Ocular Drug Delivery was valued at US$ 26590 million in the year 2024 and is projected to reach a revised size of US$ 36740 million by 2031, growing at a CAGR of 4.8% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Ocular Drug Delivery, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ocular Drug Delivery.
The Ocular Drug Delivery market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Ocular Drug Delivery market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Ocular Drug Delivery manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
OCULAR THERAPEUTIX, INC
Alimera Sciences
Allergan, Plc
EyeGate Pharma
Valeant Pharmaceuticals International, Inc
Envisia Therapeutics
Clearside Biomedical
Graybug Vision Inc
Taiwan Liposome Company
Santen Pharmaceutical
Segment by Type
Ocular Insert
Iontophoresis
Intraocular Implants
In Situ Gel & Punctal Plugs
Others
Segment by Application
Hospitals
Ambulatory Surgical Centers
Ophthalmic Clinics
Homecare Settings
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Ocular Drug Delivery manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Ocular Drug Delivery in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Ocular Drug Delivery Market Overview
1.1 Product Definition
1.2 Ocular Drug Delivery by Type
1.2.1 Global Ocular Drug Delivery Market Value Comparison by Type (2024 VS 2031)
1.2.2 Ocular Insert
1.2.3 Iontophoresis
1.2.4 Intraocular Implants
1.2.5 In Situ Gel & Punctal Plugs
1.2.6 Others
1.3 Ocular Drug Delivery by Application
1.3.1 Global Ocular Drug Delivery Market Value by Application (2024 VS 2031)
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Ophthalmic Clinics
1.3.5 Homecare Settings
1.4 Global Ocular Drug Delivery Market Size Estimates and Forecasts
1.4.1 Global Ocular Drug Delivery Revenue 2020-2031
1.4.2 Global Ocular Drug Delivery Sales 2020-2031
1.4.3 Global Ocular Drug Delivery Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Ocular Drug Delivery Market Competition by Manufacturers
2.1 Global Ocular Drug Delivery Sales Market Share by Manufacturers (2020-2025)
2.2 Global Ocular Drug Delivery Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Ocular Drug Delivery Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Ocular Drug Delivery, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Ocular Drug Delivery, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Ocular Drug Delivery, Product Type & Application
2.7 Global Key Manufacturers of Ocular Drug Delivery, Date of Enter into This Industry
2.8 Global Ocular Drug Delivery Market Competitive Situation and Trends
2.8.1 Global Ocular Drug Delivery Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Ocular Drug Delivery Players Market Share by Revenue
2.8.3 Global Ocular Drug Delivery Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Ocular Drug Delivery Market Scenario by Region
3.1 Global Ocular Drug Delivery Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Ocular Drug Delivery Sales by Region: 2020-2031
3.2.1 Global Ocular Drug Delivery Sales by Region: 2020-2025
3.2.2 Global Ocular Drug Delivery Sales by Region: 2026-2031
3.3 Global Ocular Drug Delivery Revenue by Region: 2020-2031
3.3.1 Global Ocular Drug Delivery Revenue by Region: 2020-2025
3.3.2 Global Ocular Drug Delivery Revenue by Region: 2026-2031
3.4 North America Ocular Drug Delivery Market Facts & Figures by Country
3.4.1 North America Ocular Drug Delivery Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Ocular Drug Delivery Sales by Country (2020-2031)
3.4.3 North America Ocular Drug Delivery Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Ocular Drug Delivery Market Facts & Figures by Country
3.5.1 Europe Ocular Drug Delivery Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Ocular Drug Delivery Sales by Country (2020-2031)
3.5.3 Europe Ocular Drug Delivery Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Ocular Drug Delivery Market Facts & Figures by Region
3.6.1 Asia Pacific Ocular Drug Delivery Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Ocular Drug Delivery Sales by Region (2020-2031)
3.6.3 Asia Pacific Ocular Drug Delivery Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Ocular Drug Delivery Market Facts & Figures by Country
3.7.1 Latin America Ocular Drug Delivery Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Ocular Drug Delivery Sales by Country (2020-2031)
3.7.3 Latin America Ocular Drug Delivery Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Ocular Drug Delivery Market Facts & Figures by Country
3.8.1 Middle East and Africa Ocular Drug Delivery Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Ocular Drug Delivery Sales by Country (2020-2031)
3.8.3 Middle East and Africa Ocular Drug Delivery Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Ocular Drug Delivery Sales by Type (2020-2031)
4.1.1 Global Ocular Drug Delivery Sales by Type (2020-2025)
4.1.2 Global Ocular Drug Delivery Sales by Type (2026-2031)
4.1.3 Global Ocular Drug Delivery Sales Market Share by Type (2020-2031)
4.2 Global Ocular Drug Delivery Revenue by Type (2020-2031)
4.2.1 Global Ocular Drug Delivery Revenue by Type (2020-2025)
4.2.2 Global Ocular Drug Delivery Revenue by Type (2026-2031)
4.2.3 Global Ocular Drug Delivery Revenue Market Share by Type (2020-2031)
4.3 Global Ocular Drug Delivery Price by Type (2020-2031)
5 Segment by Application
5.1 Global Ocular Drug Delivery Sales by Application (2020-2031)
5.1.1 Global Ocular Drug Delivery Sales by Application (2020-2025)
5.1.2 Global Ocular Drug Delivery Sales by Application (2026-2031)
5.1.3 Global Ocular Drug Delivery Sales Market Share by Application (2020-2031)
5.2 Global Ocular Drug Delivery Revenue by Application (2020-2031)
5.2.1 Global Ocular Drug Delivery Revenue by Application (2020-2025)
5.2.2 Global Ocular Drug Delivery Revenue by Application (2026-2031)
5.2.3 Global Ocular Drug Delivery Revenue Market Share by Application (2020-2031)
5.3 Global Ocular Drug Delivery Price by Application (2020-2031)
6 Key Companies Profiled
6.1 OCULAR THERAPEUTIX, INC
6.1.1 OCULAR THERAPEUTIX, INC Company Information
6.1.2 OCULAR THERAPEUTIX, INC Description and Business Overview
6.1.3 OCULAR THERAPEUTIX, INC Ocular Drug Delivery Sales, Revenue and Gross Margin (2020-2025)
6.1.4 OCULAR THERAPEUTIX, INC Ocular Drug Delivery Product Portfolio
6.1.5 OCULAR THERAPEUTIX, INC Recent Developments/Updates
6.2 Alimera Sciences
6.2.1 Alimera Sciences Company Information
6.2.2 Alimera Sciences Description and Business Overview
6.2.3 Alimera Sciences Ocular Drug Delivery Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Alimera Sciences Ocular Drug Delivery Product Portfolio
6.2.5 Alimera Sciences Recent Developments/Updates
6.3 Allergan, Plc
6.3.1 Allergan, Plc Company Information
6.3.2 Allergan, Plc Description and Business Overview
6.3.3 Allergan, Plc Ocular Drug Delivery Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Allergan, Plc Ocular Drug Delivery Product Portfolio
6.3.5 Allergan, Plc Recent Developments/Updates
6.4 EyeGate Pharma
6.4.1 EyeGate Pharma Company Information
6.4.2 EyeGate Pharma Description and Business Overview
6.4.3 EyeGate Pharma Ocular Drug Delivery Sales, Revenue and Gross Margin (2020-2025)
6.4.4 EyeGate Pharma Ocular Drug Delivery Product Portfolio
6.4.5 EyeGate Pharma Recent Developments/Updates
6.5 Valeant Pharmaceuticals International, Inc
6.5.1 Valeant Pharmaceuticals International, Inc Company Information
6.5.2 Valeant Pharmaceuticals International, Inc Description and Business Overview
6.5.3 Valeant Pharmaceuticals International, Inc Ocular Drug Delivery Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Valeant Pharmaceuticals International, Inc Ocular Drug Delivery Product Portfolio
6.5.5 Valeant Pharmaceuticals International, Inc Recent Developments/Updates
6.6 Envisia Therapeutics
6.6.1 Envisia Therapeutics Company Information
6.6.2 Envisia Therapeutics Description and Business Overview
6.6.3 Envisia Therapeutics Ocular Drug Delivery Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Envisia Therapeutics Ocular Drug Delivery Product Portfolio
6.6.5 Envisia Therapeutics Recent Developments/Updates
6.7 Clearside Biomedical
6.7.1 Clearside Biomedical Company Information
6.7.2 Clearside Biomedical Description and Business Overview
6.7.3 Clearside Biomedical Ocular Drug Delivery Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Clearside Biomedical Ocular Drug Delivery Product Portfolio
6.7.5 Clearside Biomedical Recent Developments/Updates
6.8 Graybug Vision Inc
6.8.1 Graybug Vision Inc Company Information
6.8.2 Graybug Vision Inc Description and Business Overview
6.8.3 Graybug Vision Inc Ocular Drug Delivery Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Graybug Vision Inc Ocular Drug Delivery Product Portfolio
6.8.5 Graybug Vision Inc Recent Developments/Updates
6.9 Taiwan Liposome Company
6.9.1 Taiwan Liposome Company Company Information
6.9.2 Taiwan Liposome Company Description and Business Overview
6.9.3 Taiwan Liposome Company Ocular Drug Delivery Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Taiwan Liposome Company Ocular Drug Delivery Product Portfolio
6.9.5 Taiwan Liposome Company Recent Developments/Updates
6.10 Santen Pharmaceutical
6.10.1 Santen Pharmaceutical Company Information
6.10.2 Santen Pharmaceutical Description and Business Overview
6.10.3 Santen Pharmaceutical Ocular Drug Delivery Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Santen Pharmaceutical Ocular Drug Delivery Product Portfolio
6.10.5 Santen Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Ocular Drug Delivery Industry Chain Analysis
7.2 Ocular Drug Delivery Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Ocular Drug Delivery Production Mode & Process Analysis
7.4 Ocular Drug Delivery Sales and Marketing
7.4.1 Ocular Drug Delivery Sales Channels
7.4.2 Ocular Drug Delivery Distributors
7.5 Ocular Drug Delivery Customer Analysis
8 Ocular Drug Delivery Market Dynamics
8.1 Ocular Drug Delivery Industry Trends
8.2 Ocular Drug Delivery Market Drivers
8.3 Ocular Drug Delivery Market Challenges
8.4 Ocular Drug Delivery Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

OCULAR THERAPEUTIX, INC
Alimera Sciences
Allergan, Plc
EyeGate Pharma
Valeant Pharmaceuticals International, Inc
Envisia Therapeutics
Clearside Biomedical
Graybug Vision Inc
Taiwan Liposome Company
Santen Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂